treatment

11th AAMDSIF and Fred Hutch Cancer Center Conference on Aplastic Anemia, MDS/AML, MPN and PNH 9:05 AM PT - 4:15 PM PT

Thumbnail for video Register Now

Topic(s)
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Bone Marrow Transplant
Myelodysplastic Syndromes (MDS)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
11th AAMDSIF and Fred Hutch Cancer Center Conference on Aplastic Anemia, MDS/AML, MPN and PNH 9:05 AM PT - 4:15 PM PT AAMDSIF and Fred Hutch Cancer Center are pleased to present the 11th Patient Conference, focusing on Aplastic Anemia, MDS, MPN, and PNH. After the presentations…

Is a Transplant Right for me? - Making Decisions

Thumbnail for video Register Now

Topic(s)
Bone Marrow Transplant
During this webinar, Dr. Joseph Pidala will discuss how patients and the medical team work together to make transplant decisions. After the presentation, there will be a panel Q & A session. Questions can be submitted in advance to help@aamds.org.

Treatment and Management of Aplastic Anemia and PNH

Thumbnail for video Register Now

Topic(s)
Aplastic Anemia
Paroxysmal Nocturnal Hemoglobinuria (PNH)
In this webinar, Catherine Bryne and Kathryn Herricks will discuss the treatment and management of aplastic anemia and PNH. At the end of the presentation, there will be a question-and-answer session. Questions can be submitted in advance at help@aamds.org.

Good job, Good health, Good life. Then: Aplastic Anemia, Followed by PNH. Daniel’s Story

In 2009, Daniel had a good job in accounting in Sydney, Australia. He had a structured, organized, healthy lifestyle. He had a devoted partner (whom he later married) and was studying for the Chartered Accountancy qualification. He rode his bike to work and played soccer. He was planning a good life ahead.

One day at the office, the receptionist pinched his arm. The next day, he saw a huge welt in the same spot.  Because a colleague urged him to get it checked out, he did.

Donor T cells on double duty: VCAR33 for AML after transplant

Original Publication Date
Article Source
External Web Content

In this issue of Blood, Mushtaq et al1 report on a phase 1/2 trial (NCT05984199, known as Vor Biopharma trial VBP301) utilizing donor-derived anti-CD33 chimeric antigen receptor–modified (CAR) T cells (VCAR33) in patients with relapsed acute myeloid leukemia (AML) following…

How I select hematopoietic cell donors in the era of posttransplant cyclophosphamide

Original Publication Date
Article Source
External Web Content

Abstract Selection of a hematopoietic progenitor cell donor for allogeneic hematopoietic cell transplantation (HCT) is essential for treatment planning; however, the parameters that define an “optimal” donor in the modern era are not well defined. Historically, donor-recipient…

Subscribe to treatment

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.